Invokana Clinical Studies

credence icon
 

Invokana Clinical Studies

CREDENCE Study

An image explaining about credence

1st Watch the animation below on the first published renal outcomes study with an SGLT2i.1

An image showing clinical study of drug

The CREDENCE trial and its value from a clinical perspective

David Wheeler, Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust looks at the findings of the CREDENCE study and the impact of Invokana on the progression of chronic kidney disease (CKD) and cardiovascular complications in patients with both type 2 diabetes and CKD.

Dr David Wheeeler Image

Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree discusses the CREDENCE study, and how Invokana has emerged as the first treatment to reduce the progression of chronic kidney disease in type 2 diabetes for 20 years.

Dr. John Wilding Image

Professor Philip Kalra, Consultant Nephrologist at Salford Royal Foundation Trust, Manchester and Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree present their key take home messages from the CREDENCE trial.

Dr. Philip Kalra Image

Julie Brake, Diabetes Nurse Consultant, Royal Liverpool University Hospital NHS Trust, and Professor Philip Kalra, Consultant Nephrologist at Salford Royal Foundation Trust, Manchester discuss the clinical value of the CREDENCE study and implications for patients with type 2 diabetes and chronic kidney disease.

Dr. Julie Brake Image

Protect T2DM patients against diabetic kidney disease (DKD) progression

In CREDENCE, Invokana + SoC showed a:

30% relative risk reduction in the primary
composite outcome compared to placebo + SoC.2

HR: 0.70 (95% CI, 0.57-0.84), p<0.0001. ARR: 18 fewer events per 1000 patient-years
  • Doubling of Serum Creatinine
  • End-Stage Kidney Disease
  • CV Death
  • Renal Death
NNT (2.5 yrs)1 22

Reduce future kidney damage and slow the decline of kidney function

In CREDENCE, Invokana + SoC showed a:

31% reduction in the amount of albuminuria.

Calculated by the geometric mean of the urinary-albumin creatinine ratio compared to placebo + SoC1 (95% CI, 26-35)

Kidney
damage

Albuminuria

Albuminuria

Invokana reduced the rate of kidney function (eGFR) decline by 60% vs placebo.1

In the chronic phase of the trial (from week 3 until the trial end)3

Difference 2.74/year (95% Cl, 2.37 - 3.11)3

Abbreviations

ARR: Absolute Risk Reduction; CI: Confidence Interval; CREDENCE: Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; eGFR: estimated Glomerular Filtration Rate; HR: Hazard Ratio; NNT: Number Needed to Treat; RRR: Relative Risk Reduction; SoC: Standard of care; SGLT2i: Sodium-Glucose Co-transporter 2 inhibitor.

References
  • 1. Perkovic V, Jardine M, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/nejmoa1811744.
  • 2. Invokana Summary of Product Characteristics. Napp Pharmaceuticals Limited. Available at: https://www.medicines.org.uk/emc/product/8855/smpc and
    https://www.medicines.org.uk/emc/product/12057/smpc [Accessed May 2021].
  • 3. Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020;31(5):1128-1139. doi:10.1681/ASN.2019111168.
Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.

CREDENCE TRIAL AND ITS VALUE FROM A CLINICAL PERSPECTIVE